|
|
 |
Cooking Tumors to Zap Cancer
|
VHL Family Forum, ISSN 1066-4130 Volume 8, Number 3
September 2000 Download a printable copy of this issue
"Health is not static; it is normal to lose it periodically in order to come back to it in a better way." -- Andrew Weil, M.D.
Optimism is essential to achievement and it is also the foundation of courage and true progress. --Nicholas Murray Butler
|
|
From an article by Bonnie Flock, Clinical Center News, June 2000, National Institutes of Health
Using radiofrequency (RF) energy to "cook" and kill cancerous tumors without affecting surrounding healthy tissue may provide an alternative to surgery for patients with kidney and other cancers, according to Dr. Bradford J. Wood, a clinical investigator with the Clinical Center's Diagnostic Radiology Department. Dr. Wood presented his research at the 25th Annual Scientific Meeting of the Society of Cardiovascular & Interventional Radiology, held this spring. This work was reported to the VHL Symposium by Dr. McClellan Walther.
"Preliminary results look promising for this technique, which is being used on tumors throughout the body, including painful tumors and cancers of the kidney, adrenal, liver, prostate, and bone," said Dr. Wood.
RF energy is fed to the tumor through a very small needle with an electrode on the tip. The needle is inserted into the tumor under imaging guidance, such as CT scan or ultrasound. The electrode generates heat up to 100 degrees Celsius. After 10 to 12 minutes of continuous contact with the tumor tissue, the RF energy "cooks" a 1-inch to 2-inch sphere, killing the tumor cells. Larger tumors an be treated by cooking overlapping spheres. The dead cells are not actually removed, but become scar tissue and eventually shrink. Typically, the outpatient procedure is performed while the patient is lightly sedated, and the patient may go home hours later, usually feeling no pain.
The term ablation means removal of a tumor by some mechanical means. RF ablation is a modification of electrosurgery or electrocautery, which has been around at least since the 1920's, according to Dr. Wood. It is finding a niche in cancer treatment, which increasingly is being customized for each patient based on the size, location, and type of tumor.
Early results from a multicenter study that included the Clinical Center look promising: of 21 kidney tumors treated, 14 (67 percent) were no longer visible on x-ray 5 months after RF treatment. One patient remains cancer-free 18 months after treatment. For kidney tumors 3 centimeters or less, 11 of 14 (79 percent) showed no activity on follow-up.
"Most of these smaller tumors were in patients with recurrent, hereditary kidney tumors. For these patients, RF may provide an effective, minimally invasive option that spares normal kidney and prolongs function," said Dr. Wood. The renal ablation procedure is sometimes referred to as "RITA" for Radiofrequency interstitial tumor ablation.
In a related Clinical Center study of tumors of the adrenal glands, 10 of 15 tumors (67 percent) showed no active disease, while the remaining patients had some tumor visible on follow-up imaging. All patients treated had x-ray evidence that most of the targeted tumor was killed by the treatment. No major complications were seen. Results are preliminary with only short-term follow-up.
In another preliminary study, RF ablation provided effective short-term pain control in 21 of 24 painful tumors. RF could eventually be an option for inoperable patients who have not responded to conventional methods, are on high-dose sedating pain medicine, or have had maximum allowable radiation, according to Dr. Wood.
"RF is less expensive, safer, and generally easier than surgery," said Dr. Wood. "However, without randomized, prospective trials and long-term results, RF is not an alternative to surgery at this point. Surgery remains the proven treatment of choice for most solitary or small liver tumors."
Collaborating with Dr. Wood on this research are Drs. Tito Fojo, Mac Walther, Steve Libutti, and Christian Pavlovich of NCI. "It is still early, but we are optimistic," said Dr. Mac Walther at the VHL Symposium. "Patients are responding very well to the therapy. We need longer-term follow-up before we can say with certainty that VHL kidney tumors treated in this way will not come back."
More information, pictures, and video of this work can be found at the following website: http://www.cc.nih.gov/drd/rfa/.
As printed in the VHL Family Forum 8:3, September 2000. For permission to reprint, please contact VHL Family Alliance, editor@vhl.org. Further information is available from the VHL Family Alliance, info@vhl.org.
|